AU2251897A - Method of treating liver disorders - Google Patents

Method of treating liver disorders

Info

Publication number
AU2251897A
AU2251897A AU22518/97A AU2251897A AU2251897A AU 2251897 A AU2251897 A AU 2251897A AU 22518/97 A AU22518/97 A AU 22518/97A AU 2251897 A AU2251897 A AU 2251897A AU 2251897 A AU2251897 A AU 2251897A
Authority
AU
Australia
Prior art keywords
treating liver
liver disorders
disorders
treating
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22518/97A
Inventor
James M. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2251897A publication Critical patent/AU2251897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
AU22518/97A 1996-02-13 1997-02-13 Method of treating liver disorders Abandoned AU2251897A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1161396P 1996-02-13 1996-02-13
US011613 1996-02-13
US2588396P 1996-09-06 1996-09-06
US025883 1996-09-06
PCT/US1997/001564 WO1997030167A1 (en) 1996-02-13 1997-02-13 Method of treating liver disorders

Publications (1)

Publication Number Publication Date
AU2251897A true AU2251897A (en) 1997-09-02

Family

ID=26682596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22518/97A Abandoned AU2251897A (en) 1996-02-13 1997-02-13 Method of treating liver disorders

Country Status (2)

Country Link
AU (1) AU2251897A (en)
WO (1) WO1997030167A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329146A1 (en) * 1998-06-01 1999-12-09 Incyte Pharmaceuticals, Inc. Carbamoyl phosphate synthase homolog
JP2002528087A (en) * 1998-10-27 2002-09-03 クルセル ホランド ベー ヴェー Improved AAV vector production
WO2001085981A2 (en) * 2000-05-05 2001-11-15 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
AU2001286273A1 (en) * 2000-08-25 2002-03-04 Interbiogen, Inc. Expression vector containing urea cycle enzyme gene, transformant thereof, and use of transformant for protein over-expression
DE602005019319D1 (en) 2004-11-26 2010-03-25 Ucl Business Plc COMPOSITIONS WITH ORNITHIN AND PHENYL ACETATE OR PHENYLBUTYRATE FOR THE TREATMENT OF HEPATIC ENZEPHALOPATHY
KR102123243B1 (en) 2009-04-03 2020-06-17 오세라 테라퓨틱스, 아이엔씨. L-ornithine phenyl acetate and methods of making thereof
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
BR112017010761B1 (en) 2014-11-24 2022-10-18 Ucl Business Plc TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STARTED CELL ACTIVATION WITH THE USE OF AMMONIA REDUCTION THERAPIES
CA2995823A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
AU2018266357B2 (en) 2017-05-11 2022-12-08 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027512A2 (en) * 1994-04-11 1995-10-19 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
CA2200869A1 (en) * 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Also Published As

Publication number Publication date
WO1997030167A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
AU4880197A (en) Method for treatment of dermatological disorders
AU6578998A (en) Method of treatment of migraine
AU2543097A (en) Method for treating pain
AU2587297A (en) Method for treating pain
AU4918796A (en) Methods of treating or preventing psychiatric disorders
AU4868599A (en) Composition for and method of treating neurological disorders
AU1496697A (en) Method of increasing testosterone
AU4518897A (en) Method of treating atherosclerosis
AU2807297A (en) Methods of treating wastewater
AU2251897A (en) Method of treating liver disorders
AU1714697A (en) Method and composition for the treatment of osteoarthritis
AU2340897A (en) Method for treating pain
AU5198898A (en) Method for treatment of glutamate related disorders
AU1735800A (en) Method of treating seizure disorders
AU2051397A (en) Method of treating alopecia
PL328925A1 (en) Method of treating bipolar disorders
AU4027097A (en) Method of treatment
AU1282099A (en) Method for treatment of disorders of attention
AUPP508798A0 (en) Method of treating psoriasis
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
AU3779595A (en) Method of treating turf
AUPO421596A0 (en) Method of maintaining turf
AUPO124196A0 (en) Method of ground treatment
AU3896397A (en) Method for treating disruptive behavior disorders
AU3149297A (en) Methods of treating hypertension